42 completed, 8 terminated, 7 unknown, 4 recruiting. 63 Phase 2, 9 Phase 1, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 63 | Completed 42, Terminated 8, Unknown 7, Recruiting 4, Withdrawn 2 |
| Phase 1 | 9 | Completed 6, Withdrawn 2, Terminated 1 |
| Phase 3 | 9 | Completed 5, Unknown 3, Terminated 1 |
Follow Leishmaniasis: new trials by email Literature Review of Leishmaniasis trials Research Report on Leishmaniasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis Metronidazole - Cutaneous Leishmaniasis | Phase 2 | Recruiting | Hayder Adnan Fawzi | 40 | 2025-02-10 | 2025-02-14 |
| Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis Levofloxacin 0.5% - Cutaneous Leishmaniasis | Phase 2 | Recruiting | Hayder Adnan Fawzi | 40 | 2025-02-09 | 2025-09-30 |
| Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate Ciprofloxacin (BAYO9867), sodium stibogluconate (Pentostam) - Cutaneous Leishmaniasis | Phase 2 | Recruiting | Al-Mustafa University College | 80 | 2025-02-07 | 2025-09-30 |
| Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis With Inhaled Pentamidine Plus Oral Miltefosine Miltefosine Oral Capsule - Mucosal Leishmaniasis | Phase 2 | Recruiting | Fundacion Nacional de Dermatologia | 30 | 2025-02-04 | 2025-02-26 |
| Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis Oral tofacitinib, Parenteral meglumine antimoniate - Cutaneous Leishmaniasis, American | Phase 2 / Phase 3 | Unknown | Hospital Universitário Professor Edgard Santos | 22 | 2023-10-01 | 2023-08-25 |
| Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly Miltefosine 50mg, Pentoxifylline 400mg, Liposomal Amphotericin B - Leishmaniasis; Brazilian, Leishmaniasis, Mucocutaneous | Phase 2 / Phase 3 | Unknown | University of Brasilia | 100 | 2022-06-22 | 2023-09-15 |
| Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients 18-Methoxycoronaridine, Glucantime - Leishmaniasis; American, Cutaneous, Drug Side Effect | Phase 2 | Unknown | Infan Industria Quimica Farmaceutica Nacional | 52 | 2021-05-01 | 2020-03-19 |
| Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis. Experimental topical (Curaleish Topical) - Leishmaniasis, Cutaneous | Phase 1 / Phase 2 | Withdrawn | Universidad de Antioquia | 2021-01-01 | 2022-06-03 | |
| A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL ChAd63-KH, Placebo - Leishmaniasis, Cutaneous | Phase 2 | Completed | University of York | 86 | 2020-04-06 | 2023-05-26 |
| Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly Liposomal amphotericin B (AmBisome®) - Cutaneous Leishmaniasis, American | Phase 1 / Phase 2 | Completed | Hospital Universitário Professor Edgard Santos | 28 | 2019-03-01 | 2024-06-07 |
| Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Miltefosine and Paromomycin, miltefosine, paromomycin - Cutaneous Leishmaniasis, American | Phase 2 / Phase 3 | Completed | Fundacion Nacional de Dermatologia | 120 | 2019-02-01 | 2021-02-02 |
| Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. Sm29 Protein, Schistosoma Mansoni, Pentavalent antimony (Sbv) - Cutaneous Leishmaniasis, American | Phase 1 / Phase 2 | Completed | Hospital Universitário Professor Edgard Santos | 20 | 2019-01-17 | 2023-08-21 |
| Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis Topical Amphotericin-B 0.4% liposomal gel - Leishmaniasis | Phase 2 | Completed | Soroka University Medical Center | 13 | 2018-01-30 | 2022-03-15 |
| Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Paromomycin Sulfate, Pentamidine Isethionate, Placebo - Leishmaniasis, Cutaneous, Leishmania Braziliensis Complex | Phase 2 / Phase 3 | Completed | Fundacion Nacional de Dermatologia | 80 | 2017-04-15 | 2021-02-02 |
| Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ Miltefosine - Cutaneous Leishmaniasis | Phase 2 | Completed | Drugs for Neglected Diseases | 130 | 2016-12-01 | 2019-09-12 |
| A Study of a New Leishmania Vaccine Candidate ChAd63-KH ChAd63-KH - Leishmaniasis, Cutaneous | Phase 2 | Completed | University of York | 24 | 2016-11-01 | 2020-01-28 |
| Miltefosine Plus IL Pentamidine for Bolivian CL miltefosine plus intralesional pentamidine - Leishmaniasis, Cutaneous | Phase 2 | Completed | Jonathan Berman | 50 | 2016-01-31 | 2018-02-27 |
| The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil Meglumine antimoniate, Miltefosine, Pentoxifylline - Leishmaniasis | Phase 2 | Unknown | University of Brasilia | 160 | 2015-08-01 | 2024-01-16 |
| Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa Miltefosine - Visceral Leishmaniasis | Phase 2 | Completed | Drugs for Neglected Diseases | 30 | 2015-05-01 | 2016-10-11 |
| Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis Immucillin DI4G, Meglumine antimoniate - Leishmaniasis, Leishmaniasis, Cutaneous | Phase 2 | Completed | Hospital Universitário Professor Edgard Santos | 50 | 2014-12-01 | 2017-09-26 |
Showing 20 of 63. Sign in to see all of them.
Leishmaniasis, Cutaneous (40) · Leishmaniasis, Mucocutaneous (12) · Leishmaniasis, Visceral (9) · Communicable Diseases (1) · Drug-Related Side Effects and Adverse Reactions (1) · Hypersensitivity, Delayed (1) · Immune System Diseases (1) · Rare Diseases (1) · Skin Diseases (1)
Euglenozoa Infections (63) · Infections (63) · Parasitic Diseases (63) · Protozoan Infections (63) · Vector Borne Diseases (63) · Skin Diseases, Infectious (54) · Skin Diseases, Parasitic (54) · Skin and Connective Tissue Diseases (54) · Skin Diseases (53) · Leishmaniasis, Cutaneous (6) · Chemically-Induced Disorders (1) · Disease Attributes (1) · Hypersensitivity (1) · Immune System Diseases (1)
miltefosine (19) · Meglumine Antimoniate (11) · liposomal amphotericin B (7) · Antimony Sodium Gluconate (6) · Paromomycin (6) · Pentoxifylline (4) · Amphotericin B (2) · Antimony (2) · Cryotherapy (2) · Pentamidine (2) · halofantrine (2) · 18-methoxycoronaridine (1) · 8-aminoquinoline (1) · Allopurinol (1) · Azithromycin (1)
U.S. Army Medical Research and Development Command (10) · Drugs for Neglected Diseases (6) · Hospital Universitário Professor Edgard Santos (6) · AB Foundation (4) · Fundacion Nacional de Dermatologia (4) · Banaras Hindu University (3) · Access to Advanced Health Institute (AAHI) (2) · Foundation Fader (2) · Hayder Adnan Fawzi (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Oswaldo Cruz Foundation (2) · University of Brasilia (2) · University of York (2) · Al-Mustafa University College (1) · Ana Rabello (1)
Brazil (14) · Bolivia (10) · United States (7) · Colombia (5) · India (5) · Sudan (5) · Iraq (3) · Peru (3) · Tunisia (3) · France (2) · Israel (2) · Kenya (2) · Ethiopia (1) · Panama (1) · Uganda (1)
Shyam Sundar, MD (3) · Afif Ben Salah, M.D., Ph.D. (2) · Armando O. Schubach, MD, PhD (2) · Ivan Dario Velez, Prof (2) · Jaime Soto, MD (2) · Paulo RL Machado, MD, PhD (2) · Afif Ben Salah,, MD, PhD (1) · Ahmed M Musa, MD PhD (1) · Ahmed Musa, MBBS (1) · Alejandro Llanos-Cuentas, M.D. (1) · Alejandro Llanos-Cuentas, MD, PhD (1) · Amir Horev, MD (1) · Ana Rabello, MD PhD (1)
PMID 23877689, PMID 18781879, PMID 19415122, PMID 20231896, PMID 20438389, PMID 21129762, PMID 21200420, PMID 21375777, PMID 21633025, PMID 21718522, PMID 23390069, PMID 24454970, PMID 26573827, PMID 27627654, PMID 27927991, PMID 28379954, PMID 28558061, PMID 30044792, PMID 30188978, PMID 30260376, PMID 30379814, PMID 33781913, PMID 35255096, PMID 36395328, PMID 37252616, PMID 39147194, PMID 39253357
2016 (1)